A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany
Open Access
- 11 April 2023
- journal article
- research article
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 21 (4) , 627-635
Abstract
Purpose Value-based pricing of new, innovative health technologies defined as pricing through economic evaluation requires the use of a basic cost-effectiveness threshold. This study presents a cost-effectiveness model that determines the cost-effectiveness threshold for life-extending new, innovative technologies based on health system opportunity costs. Methods To estimate health system opportunity costs, the study used German data and examined the period between 1896 and 2014. To this end, it determined intertemporal differences in the remaining lifetime spending and life expectancy by age and gender. To account for the age composition of the population, it weighted age-specific intertemporal changes in the remaining lifetime spending and life expectancy by the age-specific population size. To estimate life expectancy gains solely attributable to the health care system, it used aggregated data on amenable mortality. It calculated the cost-effectiveness ratio of health care spending in the German health care system on average and at the margin. Results Based on the cost-effectiveness ratio of health care spending at the margin, the threshold value for life-prolonging new, innovative technologies was at least €42,634 per life-year gained, with a point estimate of €88,107 per life-year gained. Based on the average ratio, the threshold value dropped below €34,000 per life-year gained. Conclusion This study provides new evidence on the cost-effectiveness threshold for value-based pricing of new, innovative technologies. Data from Germany suggest that a threshold value based on health care spending at the margin is considerably higher than that based on the average ratio.Keywords
Funding Information
- Frankfurt School of Finance & Management gGmbH
This publication has 20 references indexed in Scilit:
- Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness thresholdHealth Technology Assessment, 2015
- On the margins of health economics: a response to 'resolving NICE'S nasty dilemma'.Health Economics, Policy and Law, 2015
- How much does health care contribute to health gain and to health inequality? Trends in amenable mortality in New Zealand 1981–2004Australian and New Zealand Journal of Public Health, 2009
- Does health care spending improve health outcomes? Evidence from English programme budgeting dataJournal of Health Economics, 2008
- What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?Medical Care, 2008
- The Value of Medical Spending in the United States, 1960–2000New England Journal of Medicine, 2006
- Effect of healthcare on mortality: Trends in avoidable mortality in Australia and comparisons with Western EuropePublic Health, 2006
- When does quality‐adjusting life‐years matter in cost‐effectiveness analysis?Health Economics, 2004
- Cost-Effectiveness versus Cost–Utility Analysis of Interventions for Cancer: Does Adjusting for Health-Related Quality of Life Really Matter?Value in Health, 2004
- The contribution of medical care to changing life expectancy in Germany and PolandSocial Science & Medicine, 2002